drugset / Trial / NCT02387372
Plasma Pharmacokinetics (PK) & Lung Penetration of Ceftolozane/Tazobactam in Participants With Pneumonia (MK-7625A-007)
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the pharmacokinetics and lung penetration of intravenous Ceftolozane/tazobactam in critically ill participants.
Timeline
- Start
- 2015-02-05
- Primary completion
- 2017-06-15
- Completion
- 2017-06-16
Publications
- Nicolau DP, De Waele J, Kuti JL, Caro L, Larson KB, Yu B, Gadzicki E, Zeng Z, Rhee EG, Rizk ML. Pharmacokinetics and Pharmacodynamics of Ceftolozane/Tazobactam in Critically Ill Patients With Augmented Renal Clearance. Int J Antimicrob Agents. 2021 Apr;57(4):106299. doi: 10.1016/j.ijantimicag.2021.106299. Epub 2021 Feb 7.
- Caro L, Nicolau DP, De Waele JJ, Kuti JL, Larson KB, Gadzicki E, Yu B, Zeng Z, Adedoyin A, Rhee EG. Lung penetration, bronchopulmonary pharmacokinetic/pharmacodynamic profile and safety of 3 g of ceftolozane/tazobactam administered to ventilated, critically ill patients with pneumonia. J Antimicrob Chemother. 2020 Jun 1;75(6):1546-1553. doi: 10.1093/jac/dkaa049.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ceftolozane | Small molecule | 0.5 g | Intravenous |
| Subject | Ceftolozane | Small molecule | 1 g | Intravenous |
| Subject | Ceftolozane | Small molecule | 2 g | Intravenous |
| Subject | Tazobactam | Small molecule | 0.25 g | Intravenous |
| Subject | Tazobactam | Small molecule | 0.5 g | Intravenous |
| Subject | Tazobactam | Small molecule | 1 g | Intravenous |